European Patent Office Issues Its Intention to Grant Genervon Biopharmaceuticals a European Patent on Methods of Treating Neuronal Disorders Using MNTF Peptides and Analogs Thereof
Published: Dec 18, 2012
PASADENA, Calif.--(BUSINESS WIRE)--The European Patent Office notified Genervon of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. Genervon will proceed to have the patents for EPO application No. 07867451.2 issued, bringing the portfolio of Genervon’s issued Composition of Matters and Use patents to 46. This patent will grant the intellectual property rights to the use of GM600 in the preparation of a medicament for the therapeutic treatment of neuronal diseases and disorders including stroke, cerebral ischemia, spinal cord injuries (SCI), Huntington’s disease (HD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Alzheimer’s disease by intravenous delivery.